FDA Fully Approves Pfizer's Oral Antiviral Paxlovid for COVID-19 Treatment in Adults

The FDA has approved Paxlovid, an oral antiviral pill, for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19. Paxlovid is the fourth drug and the first oral antiviral pill approved by the FDA to treat COVID-19 in adults. The efficacy of Paxlovid was primarily supported by the final results of the EPIC-HR clinical trial, which showed an 86% reduction in the proportion of people with COVID-19 related hospitalization or death from any cause through 28 days of follow-up.